Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

CABAZITAXEL

CABAZITAXEL

Standard Dose
60MG/1.5ML (40MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview CABAZITAXEL is listed in Drugs@FDA under application 207736 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CABAZITAXEL Form and strength SOLUTION;INTRAVENOUS - 60MG/1.5ML (40MG/ML) Sponsor APOTEX Submission history Latest submission status date: 2024-04-04 00:00:00.

Structured Monograph

Clinical summary

Approval overview CABAZITAXEL is listed in Drugs@FDA under application 207736 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CABAZITAXEL Form and strength SOLUTION;INTRAVENOUS - 60MG/1.5ML (40MG/ML) Sponsor APOTEX Submission history Latest submission status date: 2024-04-04 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.